SCHEMBL1153349

SCHEMBL1153349

CC(C)CCC1CCC(O)CC1

nearest known ligand 0.39

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
SHBG P04278 1/20 0.38
MAPT P10636 1/20 0.33
METAP1 P53582 1/20 0.31
GBA1 P04062 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1154068 1.00 SHBG (0.38) SHBGMAPTMETAP1GBA1
SCHEMBL1153977 1.00 SHBG (0.38) SHBGMAPTMETAP1GBA1
SCHEMBL1678779 0.87
SCHEMBL6570906 0.86 MAPT (0.42) SHBGMAPTGBA1
SCHEMBL4390670 0.84 LMNA (0.46) SHBGMAPTGBA1
SCHEMBL21633983 0.81 GBA1 (0.33) MAPTMETAP1GBA1
SCHEMBL21634000 0.79 THRB (0.34) METAP1
SCHEMBL27401549 0.78 LMNA (0.32)
SCHEMBL14338745 0.77 GBA1 (0.32) GBA1
SCHEMBL1524887 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3826986-B1 NOVEL ODORANTS HAVING ROSE ODOUR SYMRISE AG (DE) 2026-03-04 EP claimed
US-20250302728-A1 FRAGRANCE COMPOSITIONS AND PRODUCTS CONVEYING A POSITIVE MOOD SYMRISE AG (DE) 2025-10-02 US claimed
EP-4526411-A1 FRAGRANCE COMPOSITIONS AND PRODUCTS CONVEYING A POSITIVE MOOD Symrise AG (DE) 2025-03-26 EP claimed
CN-119403907-A Fragrance composition and product for delivering positive emotion 西姆莱斯有限公司 2025-02-07 CN claimed
EP-4428219-A2 COMPOSITION FOR ODOUR IMPROVEMENT Symrise AG (DE) 2024-09-11 EP claimed
EP-3618798-B1 COMPOSITION FOR ODOUR IMPROVEMENT SYMRISE AG (DE) 2024-08-21 EP claimed
CN-117986090-A Novel fragrances with rose scent 西姆莱斯股份公司 2024-05-07 CN claimed
US-20240122834-A1 MEDICAMENT FOR PREVENTION AND TREATMENT OF HYPERPIGMENTATION SYMRISE AG (DE) 2024-04-18 US claimed
CN-110769804-B Composition for improving smell 西姆莱斯股份公司 2024-01-05 CN claimed
WO-2023224604-A1 FRAGRANCE COMPOSITIONS AND PRODUCTS CONVEYING A POSITIVE MOOD SYMRISE AG (DE) 2023-11-23 WO claimed
WO-2020020434-A1 NOVEL ODORANTS HAVING ROSE ODOUR SYMRISE AG (DE) 2020-01-30 WO claimed
US-20190225396-A1 PRODUCT COMPRISING A PLASTIC CONTAINER AND A SUBSTANCE COMPOSITION SYMRISE AG (DE) 2019-07-25 US claimed
EP-3507352-A1 PRODUCT COMPRISING A PLASTIC CONTAINER AND A SUBSTANCE COMPOSITION Symrise AG (DE) 2019-07-10 EP claimed
WO-2018202311-A1 COMPOSITION FOR ODOUR IMPROVEMENT SYMRISE AG (DE) 2018-11-08 WO claimed
WO-2018041354-A1 PRODUCT COMPRISING A PLASTIC CONTAINER AND A SUBSTANCE COMPOSITION SYMRISE AG (DE) 2018-03-08 WO claimed
US-7884065-B2 perfumes having rose and geranium notes SYMRISE AG (DE) 2011-02-08 US claimed
US-20100130397-A1 4-Isoamylcyclohexanol as Odiferant SYMRISE GMBH & CO. KG (DE) 2010-05-27 US claimed
EP-1797025-B1 4-ISOAMYLCYCLOHEXANOL AS ODIFERANT SYMRISE GMBH & CO KG (DE) 2008-08-13 EP claimed
EP-1797025-A1 4-ISOAMYLCYCLOHEXANOL AS ODIFERANT Symrise GmbH & Co. KG (DE) 2007-06-20 EP claimed
WO-2006035010-A1 4-ISOAMYLCYCLOHEXANOL AS ODIFERANT SYMRISE GMBH & CO. KG (DE) 2006-04-06 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240122834-A1 MEDICAMENT FOR PREVENTION AND TREATMENT OF HYPERPIGMENTATION MC1R, OR51E2, TYR SHBG 161/4885MAPT 3846/4885METAP1 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.